BioSpace News Archive

Ceapro Inc. announced that its common shares have been approved for trading onto the OTCQX® Best Market, a U.S. market that is operated by the OTC Markets Group in New York.

Company Ramps Up Commercialization of Neovasc Reducer™ and Development of Tiara™ Product Platforms, Primes for Pivotal Growth Period

IRADIMED CORPORATION announced that the Company will release its 2019 third quarter financial results before the market opens on Wednesday, October 30th.

Applied Therapeutics Inc. announced the Company will give an oral presentation of data at the American Society of Human Genetics 2019 Annual Meeting in Houston on AT-007, a central nervous system penetrant Aldose Reductase inhibitor in Phase 1/2 development for treatment of Galactosemia.

Emerald Health Therapeutics’ wholly-owned production facility, Verdélite, in St. Eustache, Québec, has received from Health Canada its license amendment permitting it to sell and distribute packaged, branded dried cannabis products directly to provincial/territorial wholesalers and authorized private retailers in accordance with provincial/territorial frameworks in Canada.

AL-S Pharma AG and TVM Capital Life Science, announced enrollment of the first patient in a multicenter Phase 1 clinical trial to evaluate AP-101 in patients with amyotrophic lateral sclerosis AP-101 is a human antibody directed against misfolded superoxide dismutase 1 The antibody has been discovered by translating genetic information of human memory B cells through Neurimmune’s Reverse Translational Medicine™ technology.

AcelRx Pharmaceuticals, Inc. announced an upcoming presentation at the Annual Meeting of the American Society of Anesthesiologists.

ArQule, Inc. announced it will report financial results for the third quarter of 2019 before the market opens on Wednesday, October 30, 2019.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the submission of a supplemental New Drug Application to the US Food and Drug Administration for Dovato as a switch treatment for HIV-1 infection in virologically suppressed adults on a stable antiretroviral regimen with no treatment failure.

Two poster presentations on ARQ 751 will highlight data from the phase 1 trial, as well as preclinical studies demonstrating the potential of ARQ 751 in combination with various therapeutic agents